{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:19:45Z","timestamp":1791256785926,"version":"4.1.0"},"reference-count":155,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"The British Heart Foundation Cardiovascular Research Centre"},{"DOI":"10.13039\/501100000853","name":"University of Glasgow","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000853","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Centre of Research Excellence"},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["RE\/18\/6\/34217"],"award-info":[{"award-number":["RE\/18\/6\/34217"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p\/>","DOI":"10.1093\/eurheartj\/ehz949","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T20:12:24Z","timestamp":1576786344000},"page":"1232-1248","source":"Crossref","is-referenced-by-count":18,"title":["The year in cardiology: heart failure"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1471-7016","authenticated-orcid":false,"given":"John G F","family":"Cleland","sequence":"first","affiliation":[{"name":"Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow , Glasgow G12 8QQ, UK"},{"name":"National Heart & Lung Institute , Imperial College, London, UK"},{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8QQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R","family":"Lyon","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute , Imperial College, London, UK"},{"name":"Royal Brompton Hospital , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"McDonagh","sequence":"additional","affiliation":[{"name":"King\u2019s College Hospital , London, UK"},{"name":"King\u2019s College London , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8QQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,1,6]]},"reference":[{"key":"2022102613574740300_ehz949-B1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jacc.2009.05.080","article-title":"Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction","volume":"55","author":"Torabi","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2022102613574740300_ehz949-B2","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"2022102613574740300_ehz949-B3","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1093\/eurheartj\/ehz394","article-title":"Implications of N-terminal pro-B-type natriuretic peptide in patients with three-vessel disease","volume":"40","author":"Zhang","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B4","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.jacc.2019.03.471","article-title":"Prevention or procrastination for heart failure? Why we need a universal definition of heart failure","volume":"73","author":"Cleland","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102613574740300_ehz949-B5","doi-asserted-by":"crossref","first-page":"1102.","DOI":"10.1001\/jamacardio.2019.3593","article-title":"Temporal trends and patterns in mortality after incident heart failure: a longitudinal analysis of 86000 individuals","volume":"4","author":"Conrad","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2022102613574740300_ehz949-B6","doi-asserted-by":"crossref","first-page":"e1002805.","DOI":"10.1371\/journal.pmed.1002805","article-title":"Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: a cohort study of 93,000 UK patients","volume":"16","author":"Conrad","year":"2019","journal-title":"PLoS Med"},{"key":"2022102613574740300_ehz949-B7","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/heartjnl-2017-312183","article-title":"Routes to diagnosis of heart failure: observational study using linked data in England","volume":"104","author":"Bottle","year":"2018","journal-title":"Heart"},{"key":"2022102613574740300_ehz949-B8","doi-asserted-by":"crossref","first-page":"e697","DOI":"10.3399\/bjgp19X705485","article-title":"Route to heart failure diagnosis in English primary care: a retrospective cohort study of variation","volume":"69","author":"Kim","year":"2019","journal-title":"Br J Gen Pract"},{"key":"2022102613574740300_ehz949-B9","article-title":"Global differences in acute heart failure patient characteristics, precipitants, point of hospital entry and inpatient management: an analysis from REPORT-HF, a worldwide, prospective heart failure disease registry","author":"Filippatos","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2022102613574740300_ehz949-B10","doi-asserted-by":"crossref","first-page":"e665","DOI":"10.1016\/S2214-109X(17)30196-1","article-title":"Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study","volume":"5","author":"Dokainish","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2022102613574740300_ehz949-B11","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jchf.2018.11.005","article-title":"Income inequality and outcomes in heart failure: a global between-country analysis","volume":"7","author":"Dewan","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2022102613574740300_ehz949-B12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ejhf.1347","article-title":"Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas","volume":"21","author":"Dewan","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B13","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jchf.2019.08.017","article-title":"MRAs in elderly HF patients: individual patient-data meta-analysis of RALES, EMPAHSIS-HF, and TOPCAT","volume":"7","author":"Ferreira","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2022102613574740300_ehz949-B14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/heartjnl-2018-313182","article-title":"Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure","volume":"105","author":"Ferreira","year":"2019","journal-title":"Heart"},{"key":"2022102613574740300_ehz949-B15","article-title":"Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial","author":"Pellicori","year":"2019","journal-title":"Eur J Heart Failure"},{"key":"2022102613574740300_ehz949-B16","article-title":"Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study","author":"Larsson","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B17","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1016\/j.mayocp.2019.04.041","article-title":"Association of fitness and grip strength with heart failure: findings from the UK biobank population-based study","volume":"94","author":"Sillars","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2022102613574740300_ehz949-B18","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/eurheartj\/ehz295","article-title":"Surgical obesity treatment and the risk of heart failure","volume":"40","author":"Jamaly","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00392-018-1302-7","article-title":"Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose-response meta-analysis","volume":"108","author":"Zhang","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2022102613574740300_ehz949-B20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamacardio.2019.0549","article-title":"Association of influenza-like illness activity with hospitalizations for heart failure: the atherosclerosis risk in communities study","volume":"4","author":"Kytomaa","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2022102613574740300_ehz949-B21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ahj.2019.02.009","article-title":"Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): rationale and design","volume":"212","author":"Loeb","year":"2019","journal-title":"Am Heart J"},{"key":"2022102613574740300_ehz949-B22","article-title":"Menopausal hormone therapy and risks of first hospitalized heart failure and its subtypes during the intervention and extended postintervention follow-up of the women's health initiative randomized trials","author":"Liu","year":"2019","journal-title":"J Card Fail"},{"key":"2022102613574740300_ehz949-B23","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1161\/CIRCULATIONAHA.118.039136","article-title":"Differential clinical profiles, exercise responses, and outcomes associated with existing HFpEF definitions","volume":"140","author":"Ho","year":"2019","journal-title":"Circulation"},{"key":"2022102613574740300_ehz949-B25","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/ejhf.1383","article-title":"Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure","volume":"21","author":"Pellicori","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijcard.2019.03.020","article-title":"Characteristics and outcome of acute heart failure patients according to the severity of peripheral oedema","volume":"285","author":"Shoaib","year":"2019","journal-title":"Int J Cardiol"},{"key":"2022102613574740300_ehz949-B27","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00392-018-1380-6","article-title":"Mode of presentation and mortality amongst patients hospitalized with heart failure? A report from the First Euro Heart Failure Survey","volume":"108","author":"Shoaib","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2022102613574740300_ehz949-B28","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1636","article-title":"Lung ultrasound: monitoring congestion in patients with heart failure","author":"Platz","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B29","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jchf.2019.07.008","article-title":"Lung ultrasound in acute heart failure: prevalence of pulmonary congestion and short- and long-term outcomes","volume":"7","author":"Platz","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2022102613574740300_ehz949-B30","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/ejhf.1499","article-title":"Expert consensus document: reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure","volume":"21","author":"Platz","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B31","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ejhf.1379","article-title":"Lung ultrasound integrated with clinical assessment for the diagnosis of acute decompensated heart failure in the emergency department: a randomized controlled trial","volume":"21","author":"Pivetta","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B32","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1604","article-title":"Lung ultrasound-guided treatment in ambulatory patients with heart failure: a randomized controlled clinical trial (LUS-HF study)","author":"Rivas-Lasarte","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B33","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ejhf.1437","article-title":"Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure","volume":"21","author":"Ter Maaten","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B34","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1001\/jamacardio.2019.1384","article-title":"Association of ambulatory hemodynamic monitoring of heart failure with clinical outcomes in a concurrent matched cohort analysis","volume":"4","author":"Abraham","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2022102613574740300_ehz949-B35","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ejhf.1478","article-title":"Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance","volume":"21","author":"Verbrugge","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B36","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/ejhf.1594","article-title":"Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis","volume":"21","author":"Jones","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B37","article-title":"The Hospital Frailty Risk Score and its association with in-hospital mortality, cost, length of stay and discharge location in patients with heart failure short running title: frailty and outcomes in heart failure","author":"Kwok","year":"2019","journal-title":"Int J Cardiol"},{"key":"2022102613574740300_ehz949-B38","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1093\/eurheartj\/ehy621","article-title":"Association between renin-angiotensin system inhibitor use and mortality\/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study","volume":"39","author":"Savarese","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B39","article-title":"Association between beta-blocker use and mortality\/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry","author":"Stolfo","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B40","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1093\/eurheartj\/ehy407","article-title":"Association is not causation: treatment effects cannot be estimated from observational data in heart failure","volume":"39","author":"Rush","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B41","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/eurheartj\/ehz158","article-title":"The continuous heart failure spectrum: moving beyond an ejection fraction classification","volume":"40","author":"Triposkiadis","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B42","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ejhf.1406","article-title":"Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology","volume":"21","author":"de Boer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B43","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/ejhf.1294","article-title":"The epicardial adipose inflammatory triad: coronary atherosclerosis, atrial fibrillation, and heart failure with a preserved ejection fraction","volume":"20","author":"Packer","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/cvr\/cvz198","article-title":"High sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes and mode of death","volume":"116","author":"Pellicori","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2022102613574740300_ehz949-B45","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1093\/eurheartj\/ehy712","article-title":"Novel endotypes in heart failure: effects on guideline-directed medical therapy","volume":"39","author":"Tromp","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B46","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ejhf.327","article-title":"Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response","volume":"17","author":"Kao","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B47","article-title":"Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets","author":"Cao","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B48","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/eurheartj\/ehz010","article-title":"The year in cardiology 2018: heart failure","volume":"40","author":"Cleland","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B49","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B50","article-title":"Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?","author":"Wehner","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B51","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B52","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/eurheartj\/ehy809","article-title":"Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction","volume":"40","author":"Obokata","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B53","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.amjcard.2019.08.018","article-title":"Prevalence and incidence of atrial fibrillation in ambulatory patients with heart failure","volume":"124","author":"Pellicori","year":"2019","journal-title":"Am J Cardiol"},{"key":"2022102613574740300_ehz949-B54","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s00392-019-01463-5","article-title":"Does rhythm matter in acute heart failure? An insight from the British Society for Heart Failure National Audit","volume":"108","author":"Anderson","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2022102613574740300_ehz949-B55","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/eurheartj\/ehz284","article-title":"Effect of catheter ablation on pre-existing abnormalities of left atrial systolic, diastolic, and neurohormonal functions in patients with chronic heart failure and atrial fibrillation","volume":"40","author":"Packer","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B56","article-title":"Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data","author":"Chen","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B57","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/eurheartj\/ehz238","article-title":"Very long-term survival and late sudden cardiac death in cardiac resynchronization therapy patients","volume":"40","author":"Barra","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B58","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz238","article-title":"Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review","author":"Barra","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B59","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/eurheartj\/ehz409","article-title":"The shocking lack of evidence for implantable cardioverter defibrillators for heart failure; with or without cardiac resynchronization","volume":"40","author":"Cleland","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B60","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.jcmg.2018.07.015","article-title":"Outcome in dilated cardiomyopathy related to the extent, location, and pattern of late gadolinium enhancement","volume":"12","author":"Halliday","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2022102613574740300_ehz949-B61","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s00392-019-01415-z","article-title":"Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction","volume":"108","author":"Rorth","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2022102613574740300_ehz949-B62","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00392-018-1378-0","article-title":"Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials","volume":"108","author":"Rossello","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2022102613574740300_ehz949-B63","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/jce.13414","article-title":"Postmortem ICD interrogation in mode of death classification","volume":"29","author":"Nikolaidou","year":"2018","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2022102613574740300_ehz949-B64","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1093\/eurheartj\/ehz109","article-title":"Cardiac resynchronization therapy non-responder to responder conversion rate in the more response to cardiac resynchronization therapy with MultiPoint Pacing (MORE-CRT MPP) study: results from Phase I","volume":"40","author":"Leclercq","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B65","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1016\/j.jacc.2019.09.017","article-title":"Echocardiographic outcomes after transcatheter leaflet approximation in patients with secondary mitral regurgitation: the COAPT trial","volume":"74","author":"Asch","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102613574740300_ehz949-B66","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1161\/CIRCULATIONAHA.119.043275","article-title":"Cost-effectiveness of transcatheter mitral valve repair versus medical therapy in patients with heart failure and secondary mitral regurgitation: results from the COAPT trial","volume":"140","author":"Baron","year":"2019","journal-title":"Circulation"},{"key":"2022102613574740300_ehz949-B67","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.jacc.2019.02.010","article-title":"Health status after transcatheter mitral-valve repair in heart failure and secondary mitral regurgitation: COAPT trial","volume":"73","author":"Arnold","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102613574740300_ehz949-B68","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"2022102613574740300_ehz949-B69","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1616","article-title":"Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years","author":"Iung","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B70","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jcmg.2018.11.006","article-title":"Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials","volume":"12","author":"Grayburn","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2022102613574740300_ehz949-B71","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/CIRCULATIONAHA.119.039612","article-title":"Contrasting effects of pharmacological, procedural, and surgical interventions on proportionate and disproportionate functional mitral regurgitation in chronic heart failure","volume":"140","author":"Packer","year":"2019","journal-title":"Circulation"},{"key":"2022102613574740300_ehz949-B72","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jchf.2019.06.011","article-title":"The REDUCE FMR trial: a randomized sham-controlled study of percutaneous mitral annuloplasty in functional mitral regurgitation","volume":"7","author":"Witte","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2022102613574740300_ehz949-B73","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/S0140-6736(19)32600-5","article-title":"Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study","volume":"394","author":"Nickenig","year":"2019","journal-title":"Lancet"},{"key":"2022102613574740300_ehz949-B74","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1016\/j.jacc.2019.09.028","article-title":"Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation","volume":"74","author":"Taramasso","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102613574740300_ehz949-B75","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/CIRCULATIONAHA.119.039609","article-title":"Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease: the COMPASS trial","volume":"140","author":"Branch","year":"2019","journal-title":"Circulation"},{"key":"2022102613574740300_ehz949-B76","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/CIRCULATIONAHA.119.041523","article-title":"Myocardial dysfunction and coronary artery disease as therapeutic targets in heart failure","volume":"140","author":"Cleland","year":"2019","journal-title":"Circulation"},{"key":"2022102613574740300_ehz949-B77","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102613574740300_ehz949-B78","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102613574740300_ehz949-B79","doi-asserted-by":"crossref","first-page":"515.","DOI":"10.1001\/jamacardio.2019.1049","article-title":"Association of rivaroxaban with thromboembolic events in patients with heart failure, coronary disease, and sinus rhythm: a post hoc analysis of the COMMANDER HF trial","volume":"4","author":"Greenberg","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2022102613574740300_ehz949-B80","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1093\/eurheartj\/ehz427","article-title":"A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial","volume":"40","author":"Mehra","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B81","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1093\/eurheartj\/ehz240","article-title":"Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial","volume":"40","author":"Morrow","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B82","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B83","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"2022102613574740300_ehz949-B84","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"2022102613574740300_ehz949-B85","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.118.037077","article-title":"Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation","volume":"139","author":"Kang","year":"2019","journal-title":"Circulation"},{"key":"2022102613574740300_ehz949-B86","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jacc.2018.11.042","article-title":"Effects of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF","volume":"73","author":"Zile","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102613574740300_ehz949-B87","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1161\/CIRCHEARTFAILURE.110.960716","article-title":"Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy","volume":"4","author":"Krum","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2022102613574740300_ehz949-B88","doi-asserted-by":"crossref","first-page":"e004962","DOI":"10.1161\/CIRCHEARTFAILURE.118.004962","article-title":"Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial","volume":"11","author":"Solomon","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2022102613574740300_ehz949-B89","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B90","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/eurjhf\/hfp120","article-title":"A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction","volume":"11","author":"Parthasarathy","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B91","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102613574740300_ehz949-B92","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med"},{"key":"2022102613574740300_ehz949-B93","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"2022102613574740300_ehz949-B94","article-title":"Effects of sacubitril-valsartan, versus valsartan, in women compared to men with heart failure and preserved ejection fraction: insights from PARAGON-HF","author":"McMurray","year":"2019","journal-title":"Circulation"},{"key":"2022102613574740300_ehz949-B95","article-title":"Prior heart failure hospitalization, clinical outcomes, and response to sacubitril\/valsartan compared with valsartan in HFpEF","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102613574740300_ehz949-B96","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacc.2018.09.081","article-title":"Differential impact of heart failure with reduced ejection fraction on men and women","volume":"73","author":"Dewan","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102613574740300_ehz949-B97","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jchf.2019.05.015","article-title":"Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"7","author":"Chandra","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2022102613574740300_ehz949-B98","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S0140-6736(19)31792-1","article-title":"Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study","volume":"394","author":"Santema","year":"2019","journal-title":"Lancet"},{"key":"2022102613574740300_ehz949-B99","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jchf.2019.01.003","article-title":"Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial","volume":"7","author":"Merrill","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2022102613574740300_ehz949-B100","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ejhf.1133","article-title":"The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis","volume":"20","author":"Linde","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B101","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8060779","article-title":"Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors","volume":"8","author":"Eickhoff","year":"2019","journal-title":"J Clin Med"},{"key":"2022102613574740300_ehz949-B102","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1111\/dom.13855","article-title":"Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes","volume":"21","author":"Dekkers","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2022102613574740300_ehz949-B103","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12933-019-0828-y","article-title":"Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives","volume":"18","author":"Cefalo","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2022102613574740300_ehz949-B104","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2022102613574740300_ehz949-B105","doi-asserted-by":"crossref","first-page":"47.","DOI":"10.1186\/s12933-019-0853-x","article-title":"Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171, 253 participants from 91 randomized controlled trials","volume":"18","author":"Yang","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2022102613574740300_ehz949-B106","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"2022102613574740300_ehz949-B107","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022102613574740300_ehz949-B108","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ejhf.1535","article-title":"Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction","volume":"21","author":"Shen","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B109","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"2022102613574740300_ehz949-B110","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102613574740300_ehz949-B111","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"2022102613574740300_ehz949-B112","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ejhf.1548","article-title":"The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B113","article-title":"Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF","author":"Martinez","year":"2019","journal-title":"Circulation"},{"key":"2022102613574740300_ehz949-B114","article-title":"Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial","author":"Kosiborod","year":"2019","journal-title":"Circulation"},{"key":"2022102613574740300_ehz949-B115","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"key":"2022102613574740300_ehz949-B116","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2022102613574740300_ehz949-B117","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores and red blood cell morphology in patients with type 2 diabetes and coronary artery disease","author":"Mazer","year":"2019","journal-title":"Circulation"},{"key":"2022102613574740300_ehz949-B118","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N Engl J Med"},{"key":"2022102613574740300_ehz949-B119","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/dom.13229","article-title":"Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis","volume":"20","author":"Packer","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2022102613574740300_ehz949-B120","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.118.036459","article-title":"Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients","volume":"139","author":"Nielsen","year":"2019","journal-title":"Circulation"},{"key":"2022102613574740300_ehz949-B121","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART cardiolink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"2022102613574740300_ehz949-B122","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ejhf.1536","article-title":"Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial","volume":"21","author":"Packer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B123","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ejhf.1596","article-title":"Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B124","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ejhf.1368","article-title":"Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU","volume":"21","author":"Maggioni","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B125","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMoa1801291","article-title":"Effects of serelaxin in patients with acute heart failure","volume":"381","author":"Metra","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102613574740300_ehz949-B126","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2019.18598","article-title":"Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: The GALACTIC Randomized Clinical Trial","volume":"322","year":"2019","journal-title":"JAMA"},{"key":"2022102613574740300_ehz949-B127","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurheartj\/ehp458","article-title":"The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study","volume":"31","author":"Mebazaa","year":"2010","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B128","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/ejhf.1533","article-title":"Controlled decongestion by reprieve therapy in acute heart failure: results of the TARGET-1 and TARGET-2 studies","volume":"21","author":"Biegus","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B129","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijcard.2018.09.085","article-title":"Percutaneous haemodynamic and renal support in patients presenting with decompensated heart failure: a multi-centre efficacy study using the Reitan Catheter Pump (RCP)","volume":"275","author":"Keeble","year":"2019","journal-title":"Int J Cardiol"},{"key":"2022102613574740300_ehz949-B130","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/jama.2019.2341","article-title":"Intramyocardial injection of mesenchymal precursor cells and successful temporary weaning from left ventricular assist device support in patients with advanced heart failure: a randomized clinical trial","volume":"321","author":"Yau","year":"2019","journal-title":"JAMA"},{"key":"2022102613574740300_ehz949-B131","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","article-title":"Genetic variants associated with cancer therapy-induced cardiomyopathy","volume":"140","author":"Garcia-Pavia","year":"2019","journal-title":"Circulation"},{"key":"2022102613574740300_ehz949-B132","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10549-014-3253-7","article-title":"Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer","volume":"149","author":"Yu","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"2022102613574740300_ehz949-B133","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","article-title":"Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study","volume":"175","author":"Lynce","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"2022102613574740300_ehz949-B134","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol"},{"key":"2022102613574740300_ehz949-B135","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.ihj.2018.06.011","article-title":"Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin","volume":"70","author":"Abuosa","year":"2018","journal-title":"Indian Heart J"},{"key":"2022102613574740300_ehz949-B136","doi-asserted-by":"crossref","first-page":"104577.","DOI":"10.1016\/j.phrs.2019.104577","article-title":"Role of cardioprotective agents on chemotherapy-induced heart failure: a systematic review and network meta-analysis of randomized controlled trials","volume":"151","author":"Li","year":"2020","journal-title":"Pharmacol Res"},{"key":"2022102613574740300_ehz949-B137","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/ejhf.1532","article-title":"Sacubitril\/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency\/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world","volume":"21","author":"Kapelios","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B138","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cardfail.2018.10.005","article-title":"Low utilization of beta-blockers among medicare beneficiaries hospitalized for heart failure with reduced ejection fraction","volume":"25","author":"Loop","year":"2019","journal-title":"J Card Fail"},{"key":"2022102613574740300_ehz949-B139","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/jama.2019.0710","article-title":"Effect of patient-centered transitional care services on clinical outcomes in patients hospitalized for heart failure: the PACT-HF randomized clinical trial","volume":"321","author":"Van Spall","year":"2019","journal-title":"JAMA"},{"key":"2022102613574740300_ehz949-B140","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ejhf.1503","article-title":"Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial","volume":"21","author":"Schulz","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B141","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ejhf.1354","article-title":"Effectiveness of the European Society of Cardiology\/Heart Failure Association website \u2018heartfailurematters.org\u2019 and an e-health adjusted care pathway in patients with stable heart failure: results of the \u2018e-Vita HF\u2019 randomized controlled trial","volume":"21","author":"Wagenaar","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B142","doi-asserted-by":"crossref","first-page":"e017765.","DOI":"10.1136\/bmjopen-2017-017765","article-title":"Effectiveness of implementation interventions in improving physician adherence to guideline recommendations in heart failure: a systematic review","volume":"8","author":"Shanbhag","year":"2018","journal-title":"BMJ Open"},{"key":"2022102613574740300_ehz949-B143","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jchf.2019.04.023","article-title":"Exercise-based rehabilitation for heart failure: cochrane systematic review, meta-analysis, and trial sequential analysis","volume":"7","author":"Taylor","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2022102613574740300_ehz949-B144","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jacc.2018.12.072","article-title":"Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure: individual participant meta-analysis","volume":"73","author":"Taylor","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102613574740300_ehz949-B145","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/ejhf.1311","article-title":"Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials","volume":"20","author":"Taylor","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2022102613574740300_ehz949-B146","first-page":"CD003331.","article-title":"Exercise-based cardiac rehabilitation for adults with heart failure","volume":"1","author":"Long","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2022102613574740300_ehz949-B147","first-page":"CD002752.","article-title":"Disease management interventions for heart failure","volume":"1","author":"Takeda","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2022102613574740300_ehz949-B148","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1177\/2047487319833507","article-title":"The cost effectiveness of REACH-HF and home-based cardiac rehabilitation compared with the usual medical care for heart failure with reduced ejection fraction: a decision model-based analysis","volume":"26","author":"Taylor","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2022102613574740300_ehz949-B149","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1177\/1474515119850011","article-title":"Caregiver outcomes of the REACH-HF multicentre randomized controlled trial of home-based rehabilitation for heart failure with reduced ejection fraction","volume":"18","author":"Wingham","year":"2019","journal-title":"Eur J Cardiovasc Nurs"},{"key":"2022102613574740300_ehz949-B150","doi-asserted-by":"crossref","DOI":"10.1002\/ehf2.12498","article-title":"Oral modified release morphine for breathlessness in chronic heart failure: a randomized placebo-controlled trial","author":"Johnson","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2022102613574740300_ehz949-B151","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"key":"2022102613574740300_ehz949-B152","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1093\/eurheartj\/ehz233","article-title":"Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study","volume":"40","author":"Ghimire","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B153","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1093\/eurheartj\/ehz395","article-title":"Digoxin-mortality: randomized vs. observational comparison in the DIG trial","volume":"40","author":"Aguirre","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B154","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1093\/eurheartj\/ehz554","article-title":"Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial","volume":"40","author":"Rohde","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102613574740300_ehz949-B155","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ejhf.748","article-title":"The effects of short-term omission of daily medication on the pathophysiology of heart failure","volume":"19","author":"Dovancescu","year":"2017","journal-title":"Eur J Heart Fail"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/12\/1232\/46645035\/eurheartj_41_12_1232.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/12\/1232\/46645035\/eurheartj_41_12_1232.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T15:21:33Z","timestamp":1666797693000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/41\/12\/1232\/5694316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,6]]},"references-count":155,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,1,6]]},"published-print":{"date-parts":[[2020,3,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehz949","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3,21]]},"published":{"date-parts":[[2020,1,6]]}}}